(Accepted 10 une 1983) Effect on intra-arterial blood pressure of slow release metoprolol combined with placebo or chlorthalidone H A KIESO, B A GOULD, S MANN, R S HORNUNG, D G ALTMAN, E B RAFTERY Abstract Thirty patients with essential hypertension participated in a double blind crossover trial in which they were randomly allocated to treatment with either once daily slow release metoprolol (200 mg) with placebo or once daily slow release metoprolol (200 mg) with chlorthalidone (25 mg). Ambulatory intra-arterial blood pressure was recorded continuously for 24-48 hours before treatment and two months after each change in regimen. The response of blood pressure and pulse rate to a standard exercise protocol that included supine rest and tilt, isometric, and dynamic bicycle exercise was measured during the same recording periods. Both treatments appreciably reduced blood pressure and pulse rate; mean daytime intra-arterial blood pressure was reduced from 174/95 mm Hg to 158/85 mm Hg by metoprolol plus placebo and to 143/78 mm Hg by metoprolol plus chlorthalidone. This reduction with the combined treatment was significantly greater than with metoprolol and placebo (p systolic ---0-001, p diastolic =0-004). Mean night time pressures were reduced from 148/78 mm Hg to 139/75 mm Hg by metoprolol plus placebo and to 116/ 61 mm Hg by metoprolol plus chlorthalidone. Again the reduction in blood pressure was significantly greater with combined treatment (p <0 001) than with metoprolol plus placebo.
Once daily slow release metoprolol is effective in controlling blood pressure, but this effect is greatly enhanced by the addition of a diuretic.
Introduction
Metoprolol is a selective beta adrenoreceptor blocking agent' that has been shown to lower the blood pressure during the day and at night and during dynamic exercise but not isometric exercise.2 Chlorthalidone is a long acting diuretic closely allied to the thiazides and the results of studies have shown that a combination of metoprolol and chlorthalidone is effective and well tolerated in mild to moderate hypertension.3 Once daily dosage with antihypertensive agents is desirable since it improves compliance,4 and metoprolol may maintain its hypotensive effect up to 26 hours after the last dose. 5 We measured the effects of a single daily dose of a slow release formulation of metoprolol combined with either placebo or chlorthalidone to assess the effectiveness of the combination in terms of both absolute reduction of blood pressure and duration of effect. We also measured the effect of both combinations on blood pressure during a standardised exercise protocol.
Patients and methods
Thirty patients with uncomplicated essential hypertension (seven women, 23 men), aged from 36 to 65 years (mean 52 years) were recruited from the hypertension clinic. Patients were included if the mean of three blood pressures taken in the outpatient clinic measured by standard indirect techniques (diastolic= Korotkoff phase V) exceeded 160 mm Hg systolic or 95 mm Hg diastolic or both. The usual contraindications to beta adrenoreceptor blocking drugs and thiazides were observed. We have row undertaken several studies over three periods of intra-arterial monitoring without complications, and an internal audit of our first 1000 cannulations has shown only a few minor complications (unpublished data). We thus feel confident that there is no contraindication to three periods of intra-arterial blood pressure monitoring in a single patient. Informed consent was obtained, and the trial was approved by the hospital ethical committee.
The patients received no antihypertensive treatment for four weeks before the first study and were then randomly allocated to receive slow release metoprolol 200 mg once daily with placebo or slow release metoprolol 200 mg with 25 mg chlorthalidone once daily, the allocation being double blind. Each patient was requested to take the tablets at 0800 and all were followed up in the hypertension clinic. After about eight weeks (range 7-9) the patients were studied a second time. Each was then switched to the alternative regimen for a further eight weeks, when a third study was performed. Each patient was seen at two weekly intervals in the hypertension clinic, where blood pressures were measured by trained nurses using standard mercury sphygmomanometers. Side effects, both volunteered and elicited by direct questioning, were recorded and compliance was checked by tablet counting. Concentrations of serum potassium, creatinine, uric acid, and blood urea were measured once before and twice during each period of treatment.
The technique of continuous intra-arterial ambulatory monitoring of blood pressure has been described.6 A standardised exercise protocol of supine rest, isometric hand grip, and graded bicycle exercise, which has been previously described,7 was carried out after insertion of the intra-arterial cannula. The techniques of analysis of intra-arterial blood pressure data have been described.8 I The intra-arterial blood pressure was computed for each hour of the day. The hourly differences between the measurements before treatment and those after treatment with metoprolol plus placebo and between the latter and metoprolol plus chlorthalidone were assessed using Student's paired t test (two tailed). Paired t tests were also used for the analysis of clinic pressures and biochemical data. combination of metoprolol and placebo was barely significant for systolic pressure (p = 0-045) and not significant (p = 0-35) for diastolic pressure. The magnitude of reduction with the combination of metoprolol and chlorthalidone was greater than that for daytime pressures (p < 0 001) when compared with metoprolol and placebo.
In crossover studies it is essential to ensure that there are no important differences in the observed efficacies of the drugs according to the order in which they were taken. The mean daytime and night time pressures were thus each examined for a possible treatment order interaction. None of the four interactions was statistically significant (p >0-05). Heart rate BIOCHEMICAL MEASUREMENTS (table III) There was a significant increase in uric acid from 359 prmol/l (6 mg/100 ml) (pre-treatment) to 447 prmol/l (7 5 mg/100 ml) after metoprolol and chlorthalidone (p<0-001) (the upper limit for our laboratory=425 jemol/l (7 1 mg/100 ml)). The same combination also raised the blood urea from 5-7 mmol/l to 6 7 mmol/l (34-40 mg/100 ml) (p < 0 01) (the upper limit = 6 5 mmol/l (40 mg/100 ml)). The serum potassium concentration was only slightly altered by metoprolol and placebo. SIDE 
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EFFECTS
Three patients withdrew from the trial because of side effects. One developed severe dyspepsia while taking metoprolol and placebo; a second developed transient ischaemic attacks while taking metoprolol and chlorthalidone; and a third developed depression and had nightmares while taking metoprolol and chlorthalidone. Of the patients who completed the trial, lethargy (four patients) and cold hands and feet (six patients) were the most frequent complaints. One patient complained of impotence and two of "gritty eyes" without objective evidence of ophthalmic lesions.
Discussion
The efficacy of metoprolol as an antihypertensive agent (on its own or combined with diuretics) has been shown in several trials,2 35 and the half life of its effect on heart rate and blood pressure has been shown to be longer than the plasma elimination half life.' Several studies have suggested that a once daily dose of metoprolol may control the blood pressure over 24 hours.2 11 Diuretics have been clearly shown to enhance the antihypertensive effects of beta adrenoreceptor blocking drugs3
and have also been shown to produce a uniform lowering of of hourly mean values of intra-arterial pressure without affecting the shape of the circadian curve.'2 This study was designed to assess the efficacy of a slow release formulation of metoprolol and to show the effect of adding a thiazide diuretic.
The results of the study show that metoprolol alone effectively lowered the daytime blood pressure but had little effect on blood pressure between 0300 and 0800. This response is closely similar to that in studies of other beta adrenoreceptor blocking blocking drugs that we have published.'3 '4 We have explained mean hourly heart rate curve before awakening clearly indicates that beta adrenoreceptor blockade is still present. Several studies from this laboratory have shown that this part of the circadian curve is reduced by alpha adrenoreceptor blockers,'5 which again suggests that the alpha receptor is important at this time of the day. Thiazide diuretics exert their antihypertensive effect by virtue of direct arteriolar vasodilatation, and we have shown that the net effect on the circadian curve is an overall lowering of values without any change in the shape of the curve.'2 The addition of a diuretic to a beta adrenoreceptor blocking drug would be expected to enhance the daytime effect and also lower the night time and early morning curve. This study shows that this is exactly what happens and suggests that the combination of a beta adrenoreceptor blocker and a diuretic is not only very effective but very desirable.
During isometric exercise metoprolol and placebo caused a reduction in the absolute pressure, and there was an even greater reduction when metoprolol was combined with chlorthalidone. Earlier studies with other beta adrenoceptor blocking agents have shown appreciable reductions of the blood pressure at low grades of dynamic work but not during higher grades. 2 The results of our study confirm this finding; however, the importance of this is difficult to assess because few patients could achieve the higher workloads.
We have shown that in patients with mild to moderate hypertension slow release metoprolol and placebo produced an appreciable fall in the blood pressure during the daytime only. Metoprolol and chlorthalidone produced an appreciably greater fall in blood pressure which was maintained over the full 24 hours. Both regimens led to a reduction in the response of the blood pressure to isometric and dynamic bicycle exercise. We conclude that adding thiazide diuretics to beta adrenoreceptor blocking drugs enhances the effect and duration of control of blood pressure.
